API
< Back to all clusters
[BUSINESS] · United States · 2 sources

started · updated

Sellas Life Sciences reports Phase 3 success for cancer vaccine

Sellas Life Sciences Group, Inc. has announced that its Phase 3 REGAL study for the peptide vaccine Galinpepimut-S (GPS) reached its primary endpoint of statistically significant overall survival in patients with acute myeloid leukemia. The study reported a median overall survival of 24.0 months for the GPS group compared to 14.7 months for the comparison therapy, with a hazard ratio of 0.59.

Following the announcement, the company's stock experienced significant volatility, with pre-market trading reaching over 28 USD, a substantial increase from the previous close of 7.47 USD.

In addition to the vaccine results, the company is also progressing with SLS009, a CDK9 inhibitor. Data regarding SLS009, which involves a combination therapy with azacitidine and venetoclax, is expected to be presented at the ASH annual meeting in December 2026. Previous data for SLS009 showed a 54% overall response rate in relapsed or refractory monocytic AML and a 57% response rate in AML with TP53 mutation.

Entities

Galinpepimut-S · Nasdaq · SELLAS Life Sciences Group, Inc. · SLS009